Trial Profile
CINJ 040804: (NJ 1108) Phase I/II Study of Ixabepilone in Combination with the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients with Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Hydroxychloroquine
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2009 Additional lead investigator (Eleff M) added as reported by New Jersey Cancer Trial Connect record.
- 25 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect; CINJ040804)
- 11 Feb 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.